Setmelanotide | search
Click here to view Setmelanotide news from 60+ newspapers.
Bookmark or Share- IMCIVREE® (setmelanotide) injectionDiscover IMCIVREE® (setmelanotide) injection, the first and only FDA-approved treatment to target an impaired MC4R pathway, a root cause of hunger and obesity in people living with Bardet-Biedl syndrome (BBS), or POMC, PCSK1, or LEPR deficiency.
- Setmelanotide - WikipediaSetmelanotide is indicated for chronic weight management (weight loss and weight maintenance for at least one year) in people six years and older with obesity due to three rare genetic conditions: pro-opiomelanocortin (POMC) deficiency, proprotein subtilisin/kexin type 1 (PCSK1) deficiency, and leptin receptor (LEPR) deficiency confirmed by ...
- Setmelanotide: Uses, Interactions, Mechanism of Action - DrugBank OnlineSetmelanotide. Star 2. Summary. Setmelanotide is setmelanotide is indicated to treat obesity caused by genetic POMC, PCSK1, or LEPR deficiencies or Bardet-Biedl syndrome. Brand Names. Imcivree. Generic Name. Setmelanotide. DrugBank Accession Number.
- FDA approves first treatment for weight management[11/27/2020] The U.S. Food and Drug Administration approved Imcivree (setmelanotide) for chronic weight management (weight loss and weight maintenance for at least one year) in patients six...
- FDA approves treatment for weight management in patients with Bardet ...The U.S. Food and Drug Administration has approved a supplemental indication for Imcivree (setmelanotide) injection for chronic weight management in adult and pediatric patients 6 years of age...
More
